title: Immunohistochemical analysis of osteoconductivity of beta-tricalcium phosphate and carbonate apatite applied in femoral and parietal bone defects in rats.
abstract: The feature of osteoconductivity, and expression of inductive BMP and transcription factors (Runx2 and Osterix) for osteoblast differentiation, which was related to conductive bone formation, were observed in experimentally created defects in rat femoral and parietal bones filled with beta-tricalcium phosphate (beta-TCP) or carbonate apatite (CAP). Femoral cortical bone defects were repaired by conductive bone formed by osteoblasts differentiated around beta-TCP and CAP, and immunohistochemical observation revealed that the osteoblasts expressed BMPs, Runx2, and Osterix. However, the repair in parietal bone defects was incomplete despite the beta-TCP and CAP filling. Only cells, which differentiated around beta-TCP or CAP, and formed conductive bone expressed BMPs, Runx2, and Osterix. These findings revealed that the osteoconductivity of calcium phosphate materials required the expression of BMPs as the prerequisite for Runx2 and Osterix expression. Therefore, it is suggested that when calcium phosphate ceramics are used as bone substitute materials, BMPs are essential for osteoconductivity.
authors.affiliation: Division of Oral Pathology, Department of Oral Pathogenesis, Asahi University School of Dentistry, Mizuho, Gifu 501-0296, Japan. take@dent.asahi-u.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takeuchi
authors.forename: Motohiko
authors.initials: M
authors.lastname: Nagayama
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Imaizumi
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsukahara
authors.forename: Junko
authors.initials: J
authors.lastname: Nakazawa
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kusaka
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Ohtomo
mesh_terms: D000818:Animals; D001031:Apatites / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000494:pharmacology; D019485:Bone Morphogenetic Proteins / Q000187:drug effects / Q000378:metabolism; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D018786:Bone Substitutes / Q000494:pharmacology*; D002130:Calcium Phosphates / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D050659:Core Binding Factor Alpha 1 Subunit / Q000187:drug effects / Q000378:metabolism; D005269:Femur / Q000187:drug effects / Q000378:metabolism / Q000601:surgery; D007150:Immunohistochemistry; D008137:Longitudinal Studies; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D010294:Parietal Bone / Q000187:drug effects / Q000378:metabolism / Q000601:surgery; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014157:Transcription Factors / Q000187:drug effects / Q000378:metabolism
chemical_list: D001031:Apatites; D001672:Biocompatible Materials; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D002130:Calcium Phosphates; D050659:Core Binding Factor Alpha 1 Subunit; C493717:Runx2 protein, rat; C495181:Sp7 protein, rat; D014157:Transcription Factors; C485817:beta-tricalcium phosphate; C030782:carboapatite